Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.

Westerhout CM, Pieper KS, James SK, Mahaffey KW, de Werf FV, Califf RM, Granger CB, Armstrong PW.

Am Heart J. 2013 Mar;165(3):354-62.e2. doi: 10.1016/j.ahj.2012.12.001. Epub 2013 Jan 15.

PMID:
23453104
2.

Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes.

Guptill JT, Mehta RH, Armstrong PW, Horton J, Laskowitz D, James S, Granger CB, Lopes RD.

Circ Cardiovasc Interv. 2013 Apr;6(2):176-83. doi: 10.1161/CIRCINTERVENTIONS.112.000159. Epub 2013 Apr 2.

3.

Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.

Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, Weaver WD, Patel MR, Granger CB, Lopes RD.

Am Heart J. 2013 Nov;166(5):913-9. doi: 10.1016/j.ahj.2013.08.006. Epub 2013 Sep 24.

PMID:
24176448
4.

Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention.

Kaul P, Fu Y, Westerhout CM, Granger CB, Armstrong PW.

Am J Cardiol. 2012 Dec 1;110(11):1555-60. doi: 10.1016/j.amjcard.2012.07.020. Epub 2012 Aug 22.

PMID:
22920928
5.
6.

ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, White HD, van 't Hof AW, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW.

Circulation. 2008 Sep 23;118(13):1335-46. doi: 10.1161/CIRCULATIONAHA.108.767772. Epub 2008 Sep 8.

7.

Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Tjandrawidjaja MC, Fu Y, Westerhout CM, Wagner GS, Granger CB, Armstrong PW; APEX-AMI Investigators.

Am J Cardiol. 2010 Sep 1;106(5):630-4. doi: 10.1016/j.amjcard.2010.04.013.

PMID:
20723636
9.

Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.

Hudson MP, Armstrong PW, O'Neil WW, Stebbins AL, Weaver WD, Widimsky P, Aylward PE, Ruzyllo W, Holmes D, Mahaffey KW, Granger CB.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):183-92. doi: 10.1161/CIRCOUTCOMES.110.945311. Epub 2011 Feb 8.

10.

Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR.

Am J Cardiol. 2012 Dec 15;110(12):1756-63. doi: 10.1016/j.amjcard.2012.08.008. Epub 2012 Sep 13.

PMID:
22981263
11.

Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI).

Danchin N, Coste P, Ferrières J, Steg PG, Cottin Y, Blanchard D, Belle L, Ritz B, Kirkorian G, Angioi M, Sans P, Charbonnier B, Eltchaninoff H, Guéret P, Khalife K, Asseman P, Puel J, Goldstein P, Cambou JP, Simon T; FAST-MI Investigators.

Circulation. 2008 Jul 15;118(3):268-76. doi: 10.1161/CIRCULATIONAHA.107.762765. Epub 2008 Jun 30.

13.

Increased neutrophil-to-lymphocyte ratio predicts persistent coronary no-flow after wire insertion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Kurtul A, Murat SN, Yarlioglues M, Duran M, Celik IE, Kilic A, Ocek AH.

Clinics (Sao Paulo). 2015 Jan;70(1):34-40. doi: 10.6061/clinics/2015(01)07.

14.

The significance of anaemia in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Bolińska S, Sobkowicz B, Zaniewska J, Chlebińska I, Boliński J, Milewski R, Tycińska A, Musiał W.

Kardiol Pol. 2011;69(1):33-9.

15.

Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M.

Eur Heart J. 2010 May;31(10):1181-7. doi: 10.1093/eurheartj/ehp597. Epub 2010 Jan 19.

PMID:
20089518
16.

Early and late outcomes after primary percutaneous coronary intervention by radial or femoral approach in patients presenting in acute ST-elevation myocardial infarction and cardiogenic shock.

Bernat I, Abdelaal E, Plourde G, Bataille Y, Cech J, Pesek J, Koza J, Jirous S, Machaalany J, Déry JP, Costerousse O, Rokyta R, Bertrand OF.

Am Heart J. 2013 Mar;165(3):338-43. doi: 10.1016/j.ahj.2013.01.012. Epub 2013 Jan 31.

PMID:
23453102
17.

A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial.

Stebbins A, Mehta RH, Armstrong PW, Lee KL, Hamm C, Van de Werf F, James S, Toftegaard-Nielsen T, Seabra-Gomes R, White HD, Granger CB; Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI Investigators).

Circ Cardiovasc Interv. 2010 Oct;3(5):414-22. doi: 10.1161/CIRCINTERVENTIONS.109.925180. Epub 2010 Sep 21.

18.

Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.

Brener SJ, Westerhout CM, Fu Y, Todaro TG, Moliterno DJ, Wagner GS, Granger CB, Armstrong PW; APEX-AMI Investigators.

Am Heart J. 2009 Nov;158(5):755-60. doi: 10.1016/j.ahj.2009.09.009. Epub 2009 Oct 3.

PMID:
19853693
19.

Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.

Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, Armstrong PW, Granger CB; APEX AMI Investigators.

JAMA. 2009 May 6;301(17):1779-89. doi: 10.1001/jama.2009.600.

PMID:
19417195
20.

Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study.

Zhang Q, Zhang RY, Qiu JP, Jin HG, Zhang JF, Wang XL, Jiang L, Liao ML, Hu J, Ding FH, Zhang JS, Shen WF.

Chin Med J (Engl). 2009 Mar 20;122(6):636-42.

PMID:
19323926

Supplemental Content

Support Center